Disclaimer
Required disclosures, medical disclaimers, and affiliate disclosures for tirzepatide.us.com.
Medical Disclaimer
The information on tirzepatide.us.com is provided for educational and informational purposes only and should not be considered medical advice, diagnosis, or treatment. Tirzepatide is a prescription medication. Always consult a qualified, licensed healthcare provider before starting, stopping, or modifying any medical treatment, including tirzepatide. This website does not diagnose conditions, prescribe medications, or replace the judgment of your prescribing clinician.
The information provided here is general and may not apply to your specific medical situation. Individual results and risks vary based on personal health history, other medications, and many other factors that can only be evaluated in person by a licensed clinician.
Affiliate Disclosure
This website earns revenue through affiliate partnerships with third-party telehealth providers and related services. When you click links on this site marked as affiliate or sponsored and complete certain actions (such as enrolling in a service), we may receive compensation at no additional cost to you. Affiliate compensation does not affect the editorial content of this site, the rankings we publish, or the recommendations we make. Provider rankings are based on objective criteria including price, transparency, provider credentials, shipping reliability, and verified user experience.
Pursuant to the Federal Trade Commission's 16 CFR Part 255 ("Guides Concerning the Use of Endorsements and Testimonials in Advertising"), this website is supported by affiliate relationships with the brands it discusses, including telehealth providers offering tirzepatide.
Drug & Trademark Information
Tirzepatide is the active ingredient in Mounjaro® and Zepbound®, manufactured by Eli Lilly and Company. Mounjaro® is FDA-approved for the treatment of type 2 diabetes. Zepbound® is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, and (since December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity.
This website is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or any pharmaceutical manufacturer. All trademarks, including Mounjaro®, Zepbound®, Ozempic®, Wegovy®, Rybelsus®, and any other referenced brand names, are the property of their respective owners and are used here for descriptive purposes only.
Compounded Medication Notice
Compounded tirzepatide is prepared by state-licensed compounding pharmacies under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded tirzepatide is not FDA-approved. Compounded medications are made on an individual basis pursuant to a valid prescription. The efficacy, safety, and quality of compounded tirzepatide may differ from commercially manufactured FDA-approved Mounjaro or Zepbound.
The FDA has issued guidance regarding compounded GLP-1 medications. The regulatory landscape continues to evolve. Patients considering compounded tirzepatide should discuss the risks and benefits with their healthcare provider and verify that the dispensing pharmacy is licensed in their state.
Calculator Disclaimer
The dosing calculator, reconstitution calculator, cost comparison engine, and dose converter on this website are provided for informational and educational purposes only. Do not adjust your medication dose without consulting your prescribing physician. Actual dosing depends on individual medical evaluation, current health status, response to treatment, and many other factors that cannot be captured by an online calculator. The calculations on this site are estimates intended to help you understand the general math of tirzepatide dosing — not to replace your prescriber's specific instructions.
Results Disclaimer
Weight loss results, side effect rates, and clinical outcomes cited on this website are based on published clinical trial data, including the SURMOUNT, SURPASS, and SURMOUNT-OSA trials. Individual results vary widely. The figures cited are population averages and may not reflect your personal outcome. Tirzepatide is intended to be used in conjunction with a reduced-calorie diet and increased physical activity. Real-world results depend on adherence, individual metabolism, dose, and many other factors.
External Links
This website contains links to third-party websites and services. We are not responsible for the content, privacy policies, or practices of any third-party sites. Inclusion of a link does not constitute endorsement.
Last Updated
This disclaimer was last updated on April 7, 2026. We may revise it from time to time as our content, business model, or regulatory environment changes.